Caitlin Marie Burk, MD | |
275 Cambridge St Ste 530, Boston, MA 02114-3108 | |
(617) 726-8708 | |
Not Available |
Full Name | Caitlin Marie Burk |
---|---|
Gender | Female |
Speciality | Pediatrics - Pediatric Allergy/immunology |
Location | 275 Cambridge St Ste 530, Boston, Massachusetts |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033640842 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | 282926 (Massachusetts) | Secondary |
2080P0201X | Pediatrics - Pediatric Allergy/immunology | 282926 (Massachusetts) | Primary |
Entity Name | Massachusetts General Physicians Organization Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay.
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Advanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based RNA analysis tools, is celebrating a significant milestone.
Fewer patients were studied as part of expedited reviews of new drugs approved by the U.S. Food and Drug Administration (FDA) in 2008 and some safety questions remain unanswered, according to a study published by JAMA Internal Medicine, a JAMA Network publication.
› Verified 3 days ago
Entity Name | The General Hospital Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay.
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Advanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based RNA analysis tools, is celebrating a significant milestone.
Fewer patients were studied as part of expedited reviews of new drugs approved by the U.S. Food and Drug Administration (FDA) in 2008 and some safety questions remain unanswered, according to a study published by JAMA Internal Medicine, a JAMA Network publication.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Caitlin Marie Burk, MD 2 Hawthorne Pl Apt 6f, Boston, MA 02114-2307 Ph: () - | Caitlin Marie Burk, MD 275 Cambridge St Ste 530, Boston, MA 02114-3108 Ph: (617) 726-8708 |
News Archive
EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® Assay.
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Advanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based RNA analysis tools, is celebrating a significant milestone.
Fewer patients were studied as part of expedited reviews of new drugs approved by the U.S. Food and Drug Administration (FDA) in 2008 and some safety questions remain unanswered, according to a study published by JAMA Internal Medicine, a JAMA Network publication.
› Verified 3 days ago
Puja Banka, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Bader 203, Boston, MA 02115 Phone: 617-355-6363 | |
Angela M. Jacques, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-726-2066 | |
Dr. Elizabeth Susan Taglauer, M.D., PH.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Cailyn Hereen Rood, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Dr. Alon Peltz, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Miki Nishitani, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Vickren Pillay, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 |